Abeona Therapeutics Inc.

ABEO · NASDAQ

Official-source baseline for Abeona Therapeutics using SEC submissions, SEC company facts, the FY2025 10-K, latest available 10-Q, filed FY2025 results release, filed launch update, 2026 proxy materials, and FDA product approval sources.

Follow Add to Watchlist Ask Question

NASDAQ ABEO Coverage Bootstrap Biotechnology Gene Therapy Rare Disease

Latest ReportMay 13, 2026Abeona Therapeutics (ABEO) Coverage Bootstrap: ZEVASKYN launch execution, manufacturing, payer access, and cash runwayView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters1 of 1 reports match

Clear filters

Add tags

Selected tags

Coverage BootstrapABEO

Clear tags

MatchAny tag All tags

Latest Thesis

Abeona Therapeutics (ABEO) Coverage Bootstrap: ZEVASKYN launch execution, manufacturing, payer access, and cash runway

May 13, 2026Research reportSlides available

Read report Open slides Discussion (0)

Abeona Therapeutics Inc.Therapeutics (ABEO) Coverage Bootstrap: ZEVASKYN launch executioMay 13, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

ReportTypeUpdatedReadActions

Abeona Therapeutics (ABEO) Coverage Bootstrap: ZEVASKYN launch execution, manufacturing, payer access, and cash runwayOfficial-source baseline for Abeona Therapeutics using SEC submissions, SEC company facts, the FY2025 10-K, latest available 10-Q, filed FY2025 results release, filed launch update, 2026 proxy materials, and FDA product approval sources.NASDAQMay 13, 2026Research reportRead Slides